GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » DeferredTaxAndRevenue

Xbrane Biopharma AB (STU:7XB) DeferredTaxAndRevenue : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Xbrane Biopharma AB's current deferred tax and revenue for the quarter that ended in Dec. 2024 was €0.00 Mil.

Xbrane Biopharma AB DeferredTaxAndRevenue Historical Data

The historical data trend for Xbrane Biopharma AB's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB DeferredTaxAndRevenue Chart

Xbrane Biopharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.

Xbrane Biopharma AB Headlines

No Headlines